Why $30 Billion in Healthcare AI Can’t Fund the Right Ideas

US digital health funding surged to $14.2 billion in 2025, a 35% year-over-year increase driven by AI mega-deals worth hundreds of millions of dollars each. Yet the companies capturing those rounds are already formed, already staffed, already producing revenue or clinical data. The researchers sitting on promising healthcare AI discoveries in university labs, the people who could become the next generation of founders, often never make it that far. The gap between a laboratory breakthrough and a company that venture capital will fund is not a minor inconvenience. It is a structural feature of the healthcare innovation funding ecosystem, one that the industry refers to as the “valley of death.” This explainer breaks down why early-stage healthcare ideas stall before reaching traditional investors, how pre-company investment models work, and what the launch of Treehub by AI Health Fund on 22 April 2026 reveals about where the market is heading.

Why promising healthcare research keeps dying before it reaches investors

A researcher develops a clinical AI model that shows early promise in a university setting. The natural next step, turning it into a product, requires capital, commercial guidance, and access to the healthcare operators who would eventually buy it. The researcher typically has none of these.

This is the valley of death: the period between an academic discovery and a startup that is structured enough for traditional venture capital to consider funding it. The gap exists not because the research is weak, but because the infrastructure connecting research to commercialisation is absent at the earliest stage.

NIH translatability research on biomedical AI, published in JAMA Network Open, found that the majority of NIH-funded studies applying artificial intelligence to clinical problems did not produce outputs that moved into practical healthcare use, providing peer-reviewed confirmation that the translation gap is a documented structural phenomenon rather than an anecdotal concern.

An investor panel at the Advanced Therapies 2026 conference noted that this gap is “particularly acute in biotech, where early planning and investor trust are essential to bridge academic research to viable ventures.”

The problem compounds across three dimensions:

• Absence of formation capital. Traditional VC does not fund ideas that have not yet become companies. Friends-and-family money is inconsistent and structurally insufficient for clinical AI.
• Lack of commercialisation guidance. Researchers are trained to publish, not to build products, negotiate with payers, or structure a company.
• Low clinical maturity at the point of discovery. Even in well-funded subsectors, clinical decision support AI shows approximately 6.8% commercial maturity across AI categories, according to a September 2024 report from Flare Capital Partners and the American Hospital Association.

Roughly $60 billion has flowed into healthcare AI over the past decade, with approximately $30 billion deployed in the last three years alone. Capital at later stages is abundant. Capital at the moment a researcher needs it most is not.

How pre-company investing works and where it fits in the funding stack

Pre-company investment is capital deployed before a formal entity exists. There is no incorporated startup, no cap table, no legal structure. The money funds the transition from research concept to something that could become a company, which distinguishes it from a pre-seed round, where at least a minimal corporate entity is already in place.

A $100,000 check at this stage is not arbitrarily small. Pre-company bridging checks typically fall in the $50,000-$200,000 range, making this figure calibrated to the stage rather than a token gesture. The scale gap becomes visible when compared to pre-seed rounds in US healthcare AI, which averaged $2-5 million in 2024-2025 according to CB Insights Q3 2025 data.

The table below maps where pre-company capital sits relative to the stages that follow it.

The $14.2 billion that flowed into US digital health in 2025 concentrated overwhelmingly in post-formation, post-product companies, confirming that the early pre-company stage remains systemically undercapitalised relative to the overall market.

What separates pre-company checks from accelerator equity deals

Pre-company checks may or may not take equity, and the terms vary significantly from traditional accelerator models. Accelerators typically invest in exchange for a fixed equity percentage in an existing company. The AI Health Fund model is designed for pre-formation participants, positioning it closer to a research grant with commercial intent than to a conventional equity-for-access arrangement.

The Treehub model: what a six-month pre-company residency actually looks like

Treehub by AI Health Fund launched on 22 April 2026 with a structure built around quarterly cohorts, each running for six months. Participants receive a $100,000 early capital injection from the fund. The programme unfolds in two distinct phases.

1. Phase one focuses on product-market fit testing and network introductions. Participants gain structured exposure to health networks, payers, and operators, the buyers and decision-makers who will ultimately determine whether a healthcare AI product survives commercially. For a researcher who has never had a commercial conversation, this is not abstract mentorship; it is direct access to the people whose purchasing decisions matter.
2. Phase two shifts to trajectory planning. This includes VC pathways for participants ready to raise formal rounds, incubator options for those needing more development time, and clinical integration routes for products requiring regulatory or hospital-system alignment before they can scale.

Founding partner Mary Minno, a former Google employee, designed the programme as a structural response to systemic healthcare inefficiencies she identified during her time in technology. Her background shaped a model that emphasises operational infrastructure alongside capital, rather than treating funding as the sole barrier.

The programme’s backers reflect a specific thesis about healthcare innovation. Tim Draper commented publicly in September 2025 on systemic flaws in US healthcare spending and the pharmaceutical market, aligning with the fund’s premise that incumbent structures fail early-stage innovators. Anne Wojcicki provided written testimony before a House oversight committee in June 2025 on biotech investments and healthcare innovation policy, reflecting continued engagement with early-stage ecosystems.

The four startups already in the portfolio and what they reveal about the fund’s thesis

Four companies currently sit in the AI Health Fund portfolio. Each illustrates a different dimension of what healthcare AI looks like at the pre-formation stage.

The thematic thread connecting these four is breadth within clinical AI rather than concentration in a single subsector. Diagnostics, behavioural tracking, hormonal monitoring, environmental health, and predictive modelling all appear, suggesting the fund’s thesis is stage-specific (pre-formation healthcare AI) rather than disease-specific.

These companies cannot be independently verified through public sources. They represent early-stage ventures not yet publicly announced, consistent with the pre-formation positioning the fund is designed to serve.

What the broader market tells us about why this model is emerging now

The timing of Treehub’s launch is not coincidental. Three macro conditions are converging to create demand for pre-company programmes in healthcare AI.

AI-enabled startups captured approximately 54% of all US digital health venture funding on a full-year 2025 basis, according to Rock Health and Fierce Healthcare.

That concentration makes the structural gap more visible, not less. When the majority of capital flows to companies that already have products, clinical data, and revenue trajectories, the distance between a promising research concept and a fundable startup widens.

Three factors are sharpening the problem simultaneously:

• Capital concentration at later stages. The largest 2025 rounds, including Abridge ($300 million Series E), Hippocratic AI ($141 million Series B), and OpenEvidence ($210 million), went to companies well past the formation stage. AI also commanded approximately a 19% valuation premium over non-AI digital health rounds in 2025, according to Rock Health, further tilting capital toward established ventures.
• Rising ROI expectations from investors. Investors increasingly demand demonstrated proof of clinical outcomes and measurable return on investment, creating a credentialing problem for researchers who have not yet formed a company, let alone generated clinical data.
• Low commercial maturity of clinical AI at the point of academic discovery. The 6.8% maturity figure from Flare Capital Partners persists even as overall funding grows, suggesting that capital alone does not resolve the translation problem.

The valuation pressure at later stages is creating a secondary incentive for institutional investors to move earlier: pre-incorporation models in healthcare VC allow funds to secure intellectual property positions before formal corporate structures exist, bypassing the 19% AI valuation premium that defined 2025 deal pricing.

STAT News reporting on the early-stage biotech funding gap noted that seed and Series A capital in life sciences fell to its lowest level in a decade during 2025, a contraction that occurred simultaneously with record aggregate investment totals, illustrating precisely how later-stage concentration can coexist with acute scarcity at the formation stage.

No comparable accelerator models featuring quarterly cohorts with explicit pre-company investments in healthcare AI were identified in available sources, positioning Treehub as early in an emerging niche rather than entering a crowded category.

Investors exploring how the capital concentration described above is playing out across the broader market in real time will find our full breakdown of Q1 2026 health tech investment trends, which examines the $4 billion raised in the quarter, the subsectors attracting the earliest-stage dollars, and the clinical validation benchmarks investors are now applying at entry.

The pre-company model is still early, and the real test is what comes next

Treehub launched eight days ago. Its portfolio companies are pre-public. The model’s effectiveness at bridging research to commercial healthcare AI has not yet been demonstrated at scale, and honest assessment requires acknowledging this directly.

Roughly $30 billion has flowed into healthcare AI over the past three years, yet clinical AI subsectors still show low commercial maturity. That unresolved tension is precisely what programmes like this are positioned to address. Tim Draper’s September 2025 commentary on systemic flaws in US healthcare spending provides context for why investor-backed, operationally focused pre-company programmes represent a different bet than pure capital deployment. The premise is that the problem is not just money; it is infrastructure, guidance, and structured access to the commercial healthcare system.

Clinical AI deployment at scale, illustrated by ventures like Echo IQ embedding decision-support software into major US health systems, represents the commercial endpoint that pre-formation companies are ultimately building toward, and the gap between a researcher’s prototype and that level of institutional integration is precisely what programmes like Treehub are designed to close.

If the model works, it represents a structural fix for the valley of death that philanthropy and government grants have historically struggled to deliver. If it does not, the gap between research and commercialisation remains as wide as it was before $14.2 billion flowed into the sector last year.

What success looks like for the pre-company funding model

Two measurable outcomes will determine whether the model delivers on its premise. The first is the proportion of cohort companies that proceed to formal VC rounds, the clearest signal that pre-company capital and guidance translated into investor-ready ventures. The second is whether clinical outcomes data from portfolio companies eventually satisfies the ROI demands that later-stage investors now require.

Comparable data from Y Combinator and Techstars healthcare tracks exists but lacks verified post-2025 figures confirming this specific pre-company structure. Treehub operates without an established benchmark, which means its early cohorts will effectively create one.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions. These statements are speculative and subject to change based on market developments and company performance.